Abrégé

Provided are a chimeric virus expressing a porcine reproductive and respiratory syndrome virus (PRRSV)-derived peptide and a use thereof as a vaccine. The chimeric virus has an excellent immune stimulating effect and is useful as a vaccine that can effectively protect against PRRSV by suppressing viral amplification in target cells.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/12 - Antigènes viraux
• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present application pertains to a vaccine against avian metapneumovirus (aMPV), specifically, to a high-titer chimeric virus using a Newcastle virus vector and, preferably, to a chimeric virus expressing both a surface antigen of aMPV subtype A and a surface antigen of aMPV subtype B, a vaccine using the chimeric virus, and an avian immunization method. The F protein, which determines the pathogenicity of Newcastle disease virus, is safe as it is identical to the sequence of the KBNP-C4152 virus, which has been used domestically and internationally for more than 10 years and has been verified for safety and effectiveness, and has excellent antibody-forming effect against aMPV.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/86 - Vecteurs viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/12 - Antigènes viraux
• A61P 31/12 - Antiviraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present specification provides: a Newcastle disease virus with improved heat resistance; a Newcastle disease vaccine comprising the virus; a polypeptide comprising an L protein in the virus; a polynucleotide encoding same; and a recombinant vector comprising the polynucleotide.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/17 - Virus de la maladie de Newcastle
• A61P 31/12 - Antiviraux

Abrégé

The present invention relates to a mutant strain of European porcine reproductive and respiratory syndrome virus, in which silencing mutation is introduced into a specific site of the genome through codon pair deoptimization, and to a use thereof. The virus mutant strain provided by the present invention is attenuated and decreases in proliferative ability in pigs, compared to the wild-type strain and, as such, can be utilized as a vaccine for prevention of European porcine reproductive and respiratory syndrome.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a chimeric virus of porcine reproductive and respiratory syndrome (PRRS) virus, the chimeric virus being usable as a vaccine. A PRRSV chimeric virus of the present invention is more attenuated than the parent strain thereof, and thus promotes the secretion of neutralizing antibodies while having low pathogenicity and high stability, thereby being usable as a vaccine in the effective prevention and treatment of PRRS diseases.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a monoclonal antibody specific to porcine circovirus 2 (PCV2) and a method for diagnosing post weaning multi-systemic wasting syndrome (PMWS) using the same. More specifically, the present invention relates to monoclonal antibodies C4-1 and C4-8 of scFV-human Cк fusion recombinant protein, which specifically bind to a decoy epitope of porcine circovirus 2, and to a method for diagnosing post weaning multi-systemic wasting syndrome using the same. The monoclonal antibody of the present invention makes it possible to determine whether an antibody against PCV2 is a neutralizing antibody by a vaccine antigen or an antibody induced by immune decoy.

Classes IPC  ?

• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
• C07K 16/46 - Immunoglobulines hybrides
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/532 - Production de composés immunochimiques marqués

Abrégé

The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV.

Classes IPC  ?

• A61K 39/17 - Virus de la maladie de Newcastle
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger

Abrégé

The present invention relates to an epitope of HN protein in Newcastle disease virus which can be recognized by an avian immune system and an antibody against the epitope, a method for detecting a Newcastle disease virus by using the antibody, and an antigenic variant of Newcastle disease virus carrying changes in the epitope. The epitope of HN protein and the antigenic variant of Newcastle disease virus can be used for developing efficient vaccines, and further, in diagnosing the Newcastle disease virus rapidly and exactly.

Classes IPC  ?

• A61K 39/17 - Virus de la maladie de Newcastle
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

The present invention relates to an epitope of HN protein in Newcastle disease virus which can be recognized by an avian immune system and an antibody against the epitope, a method for detecting a Newcastle disease virus by using the antibody, and an antigenic variant of Newcastle disease virus carrying changes in the epitope. The epitope of HN protein and the antigenic variant of Newcastle disease virus can be used for developing efficient vaccines, and further, in diagnosing the Newcastle disease virus rapidly and exactly.

Classes IPC  ?

• C07K 14/125 - Virus de la maladie de Newcastle
• A61K 39/12 - Antigènes viraux